Form 13-F position report

ESSA PHARMA INC

Reported by CITADEL ADVISORS LLC

EPIX CUSIP 29668H708 Manager CIK 0001423053

First reported at 10,883 shares this quarter.

New
% of reported 13F value < 0.01% This manager · Q2 2023
Shares 10,883 Quarter-end amount reported
Reported value $29,384 Fair value at quarter end
Consecutive quarters held 1 Through Q2 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 5485000
2021-12-31 6872000
2022-03-31 0
2023-06-30 29384
2023-09-30 16918
2023-12-31 1739806
2024-03-31 310038
2024-06-30 132158
2024-09-30 172583
2024-12-31 284683
2025-03-31 129754
2025-06-30 91866
2025-09-30 27590
2025-12-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

14 quarters
Quarterly reported position history for ESSA PHARMA INC held by CITADEL ADVISORS LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2025 Reduced 0 -144,449 (-100.0%) 0 $0 2026-02-17
Q3 2025 Added 144,449 +90,410 (167.3%) < 0.01% $27,590 2025-11-14
Q2 2025 Reduced 54,039 -28,084 (-34.2%) < 0.01% $91,866 2025-08-14
Q1 2025 Reduced 82,123 -76,918 (-48.4%) < 0.01% $129,754 2025-05-15
Q4 2024 Added 159,041 +130,562 (458.5%) < 0.01% $284,683 2025-02-14
Q3 2024 Added 28,479 +3,354 (13.3%) < 0.01% $172,583 2024-11-14
Q2 2024 Reduced 25,125 -11,393 (-31.2%) < 0.01% $132,158 2024-08-14
Q1 2024 Reduced 36,518 -227,089 (-86.1%) < 0.01% $310,038 2024-05-15
Q4 2023 Added 263,607 +258,132 (4714.7%) < 0.01% $1,739,806 2024-02-14
Q3 2023 Reduced 5,475 -5,408 (-49.7%) < 0.01% $16,918 2023-11-14
Q2 2023 New 10,883 +10,883 (0.0%) < 0.01% $29,384 2023-08-14
Q1 2022 Reduced 0 -483,897 (-100.0%) 0 $0 2022-05-16
Q4 2021 Reduced 483,897 -201,634 (-29.4%) < 0.01% $6,872,000 2022-02-14
Q3 2021 Reduced 685,531 -35,170 (-4.9%) < 0.01% $5,485,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

43 managers reported ESSA PHARMA INC for Q2 2023.

Managers reporting ESSA PHARMA INC in Q2 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BVF INC IL Unchanged 8,748,629 0 0.66% $23,621,298 21 qtrs
Bellevue Group AG Unchanged 7,898,583 0 0.3% $21,326,174 10 qtrs
PFM Health Sciences LP Added 4,204,953 +43,492 0.44% $11,353,373 5 qtrs
Soleus Capital Management L P Added 4,202,094 +56,977 1.26% $11,345,654 15 qtrs
MORGAN STANLEY Added 3,870,080 +764,865 < 0.01% $10,449,216 15 qtrs
ADAGE CAPITAL PARTNERS GP L L C Unchanged 1,042,531 0 < 0.01% $2,814,834 10 qtrs
ORBIMED ADVISORS LLC Reduced 921,940 -276,397 0.05% $2,489,238 4 qtrs
Rock Springs Capital Management LP Added 663,317 +138,373 0.04% $1,790,956 10 qtrs
MILLENNIUM MANAGEMENT LLC Added 469,002 +49,935 < 0.01% $1,266,305 12 qtrs
Rhenman & Partners Asset Management AB Unchanged 356,500 0 0.1% $962,550 11 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2023
Filed
August 14, 2023
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

Sole
10,883
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.